Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - antineoplastična sredstva - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - Иммуностимуляторы, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

eli lilly nederland b.v. - pirtobrutinib - limfom, mantel-stanica - inhibitori протеинкиназы - treatment of mantle cell lymphoma (mcl).

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastična sredstva - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - antineoplastična sredstva - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

fresenius kabi deutschland gmbh - tocilizumab - arthritis, rheumatoid; cytokine release syndrome; arthritis, juvenile rheumatoid; covid-19 virus infection; giant cell arteritis - imunosupresivi - tyenne, in combination with methotrexate (mtx), is indicated for- the treatment of severe, active and progressive rheumatoid arthritis (ra) in adults not previously treated with mtx. - the treatment of moderate to severe active ra in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (dmards) or tumour necrosis factor (tnf) antagonists. in these patients, tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tocilizumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function when given in combination with methotrexate. tyenne is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation. tyenne is indicated for the treatment of active systemic juvenile idiopathic arthritis (sjia) in patients 1 year of age and older, who have responded inadequately to previous therapy with nsaids and systemic corticosteroids. tyenne can be given as monotherapy (in case of intolerance to mtx or where treatment with mtx is inappropriate) or in combination with mtx. tyenne in combination with methotrexate (mtx) is indicated for the treatment of juvenile idiopathic polyarthritis (pjia; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with mtx. tyenne can be given as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. tyenne is indicated for the treatment of chimeric antigen receptor (car) t cell-induced severe or life-threatening cytokine release syndrome (crs) in adults and paediatric patients 2 years of age and older. tyenne is indicated for the treatment of giant cell arteritis (gca) in adult patients.

Եվրոպական Միություն - խորվաթերեն - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland - sukcinata prucalopride - zatvor - ostali lijekovi za zatvor - resolor je indiciran za simptomatsko liječenje kronične zatvora kod odraslih kod kojih laksativi ne daju adekvatno olakšanje.

Խորվաթիա - խորվաթերեն - HALMED (Agencija za lijekove i medicinske proizvode)

ferrer internacional s.a., 94 gran via carlos iii, barcelona, Španjolska - treprostinilnatrij - otopina za infuziju - 1 mg/ml - urbroj: jedan ml sadrži 1 mg treprostinila u obliku treprostinilnatrija. jedna bočica s 20 ml otopine sadrži 20 mg treprostinila u obliku treprostinilnatrija (natrijeva sol stvara se in situ tijekom proizvodnje lijeka)

Խորվաթիա - խորվաթերեն - HALMED (Agencija za lijekove i medicinske proizvode)

ferrer internacional s.a., 94 gran via carlos iii, barcelona, Španjolska - treprostinilnatrij - otopina za infuziju - 10 mg/ml - urbroj: jedan ml sadrži 10 mg treprostinila u obliku treprostinilnatrija. jedna bočica s 20 ml otopine sadrži 200 mg treprostinila u obliku treprostinilnatrija (natrijeva sol stvara se in situ tijekom proizvodnje lijeka)

Խորվաթիա - խորվաթերեն - HALMED (Agencija za lijekove i medicinske proizvode)

ferrer internacional s.a., 94 gran via carlos iii, barcelona, Španjolska - treprostinilnatrij - otopina za infuziju - 2,5 mg/ml - urbroj: jedan ml sadrži 2,5 mg treprostinila u obliku treprostinilnatrija. jedna bočica s 20 ml otopine sadrži 50 mg treprostinila u obliku treprostinilnatrija (natrijeva sol stvara se in situ tijekom proizvodnje lijeka)